comprehensive -WSS

comprehensive

author：hotspot 2025-09-14 10:00:21 - browse：32137

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： The Affordable Care Act has saved billions in health care costs

hotspot

WSS

ASCO: Palliative care found as helpful given virtually as in person

With trial win, GSK could get blood cancer drug back on market

ASCO: AstraZeneca says CAR

Merck, Johnson & Johnson CEOs will testify on high drug prices

Why Medicare shouldn’t cover every FDA

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Why you shouldn’t ask, “What country has the best health care?”

Drug repurposing or repositioning? The language matters

Letters to First Opinion on caregivers, digital health, and more

Sports medicine is finally prioritizing gender equality

Ultragenyx gene therapy for rare liver ailment succeeds in late

United colonoscopy coverage change 'may cost lives,' doctors say

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Jerome Adams on the need for new antivirals for Covid

Biogen walks away from Aduhelm, years after polarizing approval

leisure time

FTC sues over Novant Health acquisition of two N.C. hospitals

New clues to why women have higher risk of autoimmune disorders

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

FTC sues over Novant Health acquisition of two N.C. hospitals

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Reconstructing family trees of blood cells may help predict disease

hotspot

explore

hotspot

focus